Review article · 2026 · Open access

Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications

Jadala Chetna, Shweta Mishra, Gal Reddy Potuganti, Savio Cardoza, Ganga Reddy Velma

RSC Advances, 16(24), 21967–22005 · Published 1 January 2026 · DOI 10.1039/d6ra00737f

Free PDFView at the publisherCite this paper

In brief

“Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications” is a 2026 review article by Jadala Chetna and 4 co-authors, published in RSC Advances. OpenAlex counts 15 citations as of 15 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at RSC Advances.

Citations
15
Most cited in
2026 (15)
Field-weighted impact
7.32
References
136
Authors
5

Abstract

Nitrogen-containing heterocycles (N-Hets) are among the most prevalent and versatile structural motifs in pharmaceuticals, serving as key scaffolds in over 85% of biologically active small molecules. Their structural diversity and functional versatility have made them integral components of both U.S. Food and Drug Administration (FDA) approved and investigational drug molecules, modulating biological activity across a range of molecular targets. In 2025, the FDA approved 26 small-molecule drugs featuring N-Het frameworks, spanning multiple therapeutic areas, including oncology, metabolic disorders, infectious diseases, and rare/orphan conditions. This review offers a comprehensive overview of these newly approved compounds, emphasizing their biological activity and synthetic approaches. Special attention is given to drug-target interactions, focusing on receptor binding and highlighting the important role of N-Hets in medicinal chemistry. By exploiting the intrinsic chemical properties of N-Hets and leveraging modern synthetic methodologies, these scaffolds continue to drive the discovery of therapeutically relevant molecules, highlighting their sustained significance in modern drug discovery.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chetna, J., Mishra, S., Potuganti, G. R., Cardoza, S., & Velma, G. R. (2026). Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications. RSC Advances, 16(24), 21967–22005. https://doi.org/10.1039/d6ra00737f

MLA 9

Chetna, Jadala, et al. “Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications.” RSC Advances, vol. 16, no. 24, 2026, pp. 21967–22005. https://doi.org/10.1039/d6ra00737f.

Chicago

Chetna, Jadala, Shweta Mishra, Gal Reddy Potuganti, Savio Cardoza, and Ganga Reddy Velma. 2026. “Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications.” RSC Advances 16 (24): 21967–22005. https://doi.org/10.1039/d6ra00737f.

Harvard

Chetna, J. et al. (2026) ‘Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications’, RSC Advances, 16(24), pp. 21967–22005. doi:10.1039/d6ra00737f.

IEEE

J. Chetna, S. Mishra, G. R. Potuganti, S. Cardoza, and G. R. Velma, “Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications,” RSC Advances, vol. 16, no. 24, pp. 21967–22005, 2026, doi: 10.1039/d6ra00737f.

BibTeX

@article{chetna2026nitrogen,
  title     = {{Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications}},
  author    = {Chetna, Jadala and Mishra, Shweta and Potuganti, Gal Reddy and Cardoza, Savio and Velma, Ganga Reddy},
  journal   = {RSC Advances},
  year      = {2026},
  volume    = {16},
  number    = {24},
  pages     = {21967--22005},
  doi       = {10.1039/d6ra00737f},
  url       = {https://doi.org/10.1039/d6ra00737f}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity

  • nitrogen heterocycles
  • FDA-approved drugs
  • drug-target interactions
  • receptor binding
  • drug discovery
  • oncology drugs
  • metabolic disorders
  • infectious diseases

Work with this paper

Most-cited papers in Chemistry

All highly cited Chemistry papers

Questions about this paper

How do I cite this paper in APA style?

Chetna, J., Mishra, S., Potuganti, G. R., Cardoza, S., & Velma, G. R. (2026). Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications. RSC Advances, 16(24), 21967–22005. https://doi.org/10.1039/d6ra00737f

How many times has this paper been cited?

15 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at RSC Advances.

Who wrote this paper?

Jadala Chetna, Shweta Mishra, Gal Reddy Potuganti, Savio Cardoza, Ganga Reddy Velma.

What is the DOI of this paper?

10.1039/d6ra00737f. The permanent link is https://doi.org/10.1039/d6ra00737f.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.